NASDAQ:VRAY

ViewRay Stock Forecast, Price & News

$3.00

-0.05 (-1.64 %)

(As of 10/26/2020 12:00 AM ET)

Add

Compare

Today's Range

$2.94

Now: $3.00▼

$3.09

50-Day Range

$2.78

MA: $3.13▼

$3.50

52-Week Range

$1.11

Now: $3.00▼

$4.88

Volume307,864 shs

Average Volume1.74 million shs

Market Capitalization$443.84 million

P/E RatioN/A

Dividend YieldN/A

Beta0.64

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Beat the Market (BTM) Rank^™

3.1 Analyst's Opinion

Consensus Rating
ViewRay has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $4.25, ViewRay has a forecasted upside of 41.7% from its current price of $3.00.
Amount of Analyst Coverage
ViewRay has received no research coverage in the past 90 days.

2.8 Community Rank

Outperform Votes
ViewRay has received 275 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ViewRay has received 223 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ViewRay has received 55.22% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ViewRay and other stocks. Vote “Outperform” if you believe VRAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ViewRay does not currently pay a dividend.
Dividend Growth
ViewRay does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ViewRay insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 15.48% of the stock of ViewRay is held by insiders.
Percentage Held by Institutions
83.03% of the stock of ViewRay is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ViewRay are expected to grow in the coming year, from ($0.71) to ($0.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ViewRay is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ViewRay is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ViewRay has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.51 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRAY

Previous Symbol

CUSIPN/A

CIK1597313

Webwww.viewray.com

Phone440-703-3210

Employees309

Debt

Debt-to-Equity Ratio0.26

Current Ratio3.90

Quick Ratio3.19

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$87.78 million

Price / Sales5.06

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.47 per share

Price / Book2.04

Profitability

EPS (Most Recent Fiscal Year)($1.18)

Net Income$-120,200,000.00

Net Margins-166.74%

Return on Equity-63.41%

Return on Assets-36.34%

Miscellaneous

Outstanding Shares147,945,000

Market Cap$443.84 million

Next Earnings Date11/5/2020 (Confirmed)

OptionableOptionable

$3.00

-0.05 (-1.64 %)

(As of 10/26/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.

ViewRay (NASDAQ:VRAY) Frequently Asked Questions

How has ViewRay's stock been impacted by COVID-19 (Coronavirus)?

ViewRay's stock was trading at $1.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VRAY stock has increased by 77.5% and is now trading at $3.00.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of ViewRay?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ViewRay.

When is ViewRay's next earnings date?

ViewRay is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for ViewRay.

How can I listen to ViewRay's earnings call?

ViewRay will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) posted its quarterly earnings data on Thursday, July, 30th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.02. The firm earned $14.22 million during the quarter, compared to analysts' expectations of $5.81 million. ViewRay had a negative net margin of 166.74% and a negative return on equity of 63.41%.
View ViewRay's earnings history.

What price target have analysts set for VRAY?

7 analysts have issued 12 month price objectives for ViewRay's stock. Their forecasts range from $2.00 to $8.00. On average, they anticipate ViewRay's stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 41.7% from the stock's current price.
View analysts' price targets for ViewRay.

Who are some of ViewRay's key competitors?

Some companies that are related to ViewRay include InMode (INMD), BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), Zynex (ZYXI), Zynex (ZYXI), Semler Scientific (SMLR), Cutera (CUTR), TransMedics Group (TMDX), Stereotaxis (STXS), Stereotaxis (STXS), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Fonar (FONR) and Edap Tms (EDAP).
View all competitors.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

Who are ViewRay's key executives?

ViewRay's management team includes the following people:

Mr. Scott William Drake, Pres, CEO & Director (Age 52, Pay $1.23M)
Mr. Shahriar Matin, Chief Operating Officer (Age 45, Pay $671.21k)
Dr. James F. Dempsey, Chief Scientific Officer (Age 49, Pay $468.31k)
Mr. Zachary William Stassen, Chief Financial Officer
Ms. Michaella Gallina, VP. Chief of Staff and Head of Investor Relations & Communications

When did ViewRay IPO?

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.60%), Hodges Capital Management Inc. (0.06%) and FNY Investment Advisers LLC (0.01%). Company insiders that own ViewRay stock include James F Dempsey, Scott William Drake and Shahriar Matin.
View institutional ownership trends for ViewRay.

Which major investors are selling ViewRay stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A..
View insider buying and selling activity for ViewRay.

Which major investors are buying ViewRay stock?

VRAY stock was acquired by a variety of institutional investors in the last quarter, including Hodges Capital Management Inc., and FNY Investment Advisers LLC. Company insiders that have bought ViewRay stock in the last two years include Scott William Drake, and Shahriar Matin.
View insider buying and selling activity for ViewRay.

How do I buy shares of ViewRay?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $3.00.

How big of a company is ViewRay?

ViewRay has a market capitalization of $443.84 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ViewRay employs 309 workers across the globe.

What is ViewRay's official website?

The official website for ViewRay is www.viewray.com.

How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings